Active Biotech's Laquinimod Fails to Meet Primary Endpoint in Phase II Trial
The primary endpoint of brain atrophy as defined by PBVC from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.
Source: BioSpace
The primary endpoint of brain atrophy as defined by PBVC from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.
Source: BioSpace